← Back to screener

Candel Therapeutics, Inc. CADL

Rank #2507 · Nasdaq · $0.6B market cap
Audited by KPMG LLP, no going-concern flag in the latest filing.
Score
11.3
P/E
-11.1
P/B
47.89
ROE
-432.9%
Op. Margin
–%
Debt Ratio
318%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -11.1x, P/B 47.89x. Ranks in the top 88% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -432.9%. Ranks in the top 99% of the universe.

Safety ★☆☆☆☆
Weak

Debt ratio 318%. Ranks in the top 73% of the universe. Above 200% signals meaningful leverage risk.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Valuation is the relative strength (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2021$0.0B$-0.0B$-0.0B$-0.0B-11048.0-159
2022$0.0B$-0.0B$-0.0B$-0.0B-20580.8-106
2023$0.0B$-0.0B$-0.0B$0.1B-27777.647
2024–$-0.0B$-0.0B$0.0B–60
2025–$-0.0B$-0.1B$0.0B–318

← See the full screener